Sartorius is a corporate partner of the Healthcare Businesswomen s Association
USA - English
Share this article
Share this article
GÖTTINGEN, Germany, March 6, 2021 /PRNewswire/ The life science group Sartorius has joined the Healthcare Businesswomen s Association (HBA) as a corporate partner. The purpose of this global non–profit organization founded in the USA is to promote women s business networks and career advancement in the life sciences, thus achieving gender parity in leadership positions in this sector. The HBA has more than 10,000 individual members and around 150 corporate partners. Besides offering career conferences and education, the organization provides a mentoring program in which a tandem of women at different career levels and from different healthcare companies network to consult on career development topics. Sartorius active engagement in the Healthcare Businesswomen s Association came about at the suggestion of the Group s own women s network initiat
Sartorius looks back on a very successful 2020 and expects further strong growth
USA - English
Outlook for the current year: sales projected to increase by 19 percent to 25 percent
Accelerated and greater ramp-up of production capacities in all geographies; CAPEX ratio of 15 percent expected for 2021
Group management raises sales target for 2025 to about 5 billion euros
Creation of more than 1,000 new jobs on average per year
News provided by
Share this article
Share this article
GOTTINGEN, Germany, Feb. 18, 2021 /PRNewswire/ The life science group Sartorius confirmed its preliminary figures for 2020 upon the release of its annual report. Group sales revenue surged by 30.2 percent to nearly 2,336 million euros in constant currencies (reported: +27.8 percent). Order intake
Resolutions of the Supervisory Board of Sartorius AG
USA - English
- Dividend proposal of 0.71 euros per preference share and 0.70 euros per ordinary share
News provided by
Share this article
Share this article
GÖTTINGEN, Germany, Feb. 11, 2021 /PRNewswire/ The Supervisory Board of Sartorius AG resolved at its meeting today to approve an early extension of the appointments of René Fáber as a member of the Executive Board and Head of the Bioprocess Solutions Division, as well as of Gerry Mackay as a member of the Executive Board and Head of the Lab Products & Services Division.
René Fáber (45) has been working for Sartorius since 2002 and has been an Executive Board member of Sartorius AG since January 2019. His appointment has now been extended by five years until December 31, 2026. Gerry Mackay (58) joined Sartorius in 2015 through the acquisition of BioOutsource and has been an Executive Board member of Sartorius AG also since January 2019. The Supervisory Bo
Sartorius closes 2020 with strong growth to well over 2 billion euros and a further increase in profitability
USA - English
- Preliminary results for the full year of 2020: Order intake up 49.0 percent; sales revenue up 30.2 percent; underlying EBITDA margin climbs to 29.6 percent
- Bioprocess Solutions Division with a sharp rise in sales revenue and earnings and a key role as a provider of essential technologies for vaccine production
- Significant double-digit growth in the Lab Products & Services Division despite a challenging first half due to the pandemic
- Number of employees rises by 17.7 percent to more than 10,600
- Strong outlook for 2021: Sales revenue set to increase by 19 percent to 25 percent
Posted January 6th, 2021 for Sartorius Göttingen, January 6, 2021
Proposed transaction builds on both companies’ strategic R&D partnership
Strengthens Sartorius position in downstream bioprocessing The life science company Sartorius today announced it has entered into an agreement through its subgroup Sartorius Stedim Biotech to acquire the chromatography process equipment division of Novasep. The parties agreed not to disclose the purchase price until the necessary regulatory approvals have been obtained. Novasep’s division expects to generate sales revenue of approximately 37 million euros in 2020 at double-digit profit margins and employs approximately 100 people, the majority of whom work at its Pompey site in northern France and some in the USA, China and India. The proposed transaction is subject to antitrust approvals and the information and consultation of Novasep’s works council and is expected to close during the first half of 2021.